MonCap Fertility Gamma, L.P.

The absence of prior EDGAR filings from this manager signals either a debut institutional raise or a predecessor operating outside SEC filing requirements, making this the first documented vehicle to track the GP's strategic direction and suggesting LPs should verify whether MonCap has operated prior funds through other legal entities or audit trails.

A mid-2026 filing for a $40M fertility-focused venture fund aligns with sustained institutional interest in reproductive health and family-building as an LP allocation category, though the pre-existing-relationships-only exemption constrains the raise to existing network capital rather than broad market testing.

Before committing, LPs should confirm whether Jonathan Sockol carries key-person status and what happens to fund governance if he departs, and verify whether MonCap MM II represents a genuine co-investment parallel or a fee-sharing arrangement that could create conflicts over deal flow allocation between the two entities.